Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Macula lutea

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Macula lutea. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-002101-39 Sponsor Protocol Number: MD7111396 Start Date*: 2008-09-25
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001301-10 Sponsor Protocol Number: EOP1009 Start Date*: 2004-06-14
    Sponsor Name:PFIZER
    Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOV...
    Medical condition: AGE-RELATED MACULAR DEGENERATION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-006014-18 Sponsor Protocol Number: 1419 Start Date*: 2005-12-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study.
    Medical condition: Macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004487-53 Sponsor Protocol Number: 2312/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration.
    Medical condition: Exudative and atrophic age-related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001418-17 Sponsor Protocol Number: trattamento con bevacizumab nella Start Date*: 2007-11-25
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: efficacy of treatment with bevacizumab,in the macular degeneration.
    Medical condition: macular degeneretion aging dependent.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003204-12 Sponsor Protocol Number: ICI21/00025 Start Date*: 2022-03-16
    Sponsor Name:Consorcio PSMAR
    Full Title: Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-...
    Medical condition: age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007744-98 Sponsor Protocol Number: 138/2007/O/Sper Start Date*: 2008-03-04
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: INTERFERON alpha2 (IFN alpha2) as anti-angiogenic agent for the treatment of neovascular age-related macular degeneration: a pilot study.
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000946-37 Sponsor Protocol Number: 2019-06 Start Date*: 2020-11-30
    Sponsor Name:Assistance Publique-Hôpitaux de Marseille
    Full Title: Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients.
    Medical condition: Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003261-14 Sponsor Protocol Number: R01 Start Date*: 2006-08-28
    Sponsor Name:Retinaklinikken Omnia
    Full Title: A randomized pilot study comparing the safety and efficacy of intravireal triamcinolone acetonide given 7 days prior to or after Photodynamic therapy with Visudyne in patients with subfoveal choroi...
    Medical condition: Patients with age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005259-20 Sponsor Protocol Number: OFT-ETAMSILATO-4.2.1 Start Date*: 2015-02-13
    Sponsor Name:Investigacion Independiente
    Full Title: FASE IV-II CLINICAL TRIAL, PROOF OF CONCEPT, RANDOMIZED, SIMULATED CONTROLLED TREATMENT, DOUBLE BLINDED AND UNICENTRIC WITH TWO PARALLEL GROUPS, TO EVALUATE SAFETY AND EFFICACY OF INTRAVITREAL ADMI...
    Medical condition: Aged related macula degeneration (ARMD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003320-36 Sponsor Protocol Number: 190342-038 Start Date*: 2015-03-02
    Sponsor Name:Allergan Limited
    Full Title: Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)
    Medical condition: Geographic Atrophy Secondary to Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015681-55 Sponsor Protocol Number: C-09-023 Start Date*: 2010-03-18
    Sponsor Name:Alcon Research, Ltd.
    Full Title: A Dose-Escalation Study of AL-39324 Suspension versus Lucentis™ for the Treatment of Exudative Age-Related Macular Degeneration
    Medical condition: Exudative Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006073-84 Sponsor Protocol Number: MD7108240 Start Date*: 2008-02-25
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with ...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003431-37 Sponsor Protocol Number: CRFB002AES03T Start Date*: 2013-01-02
    Sponsor Name:Sociedad Española de retina y Vítreo
    Full Title: A 12-month, phase IV, open-label, randomized, 2-arm, multicenter study assessing the efficacy and safety of a flexible individualized ?wait and extend? PRN regimen versus a PRN stabilization-cri...
    Medical condition: pacientes naive con degeneración macular relacionada con la edad
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10012148 Degeneration macular LLT
    14.1 10015919 - Eye disorders 10025409 Macular degeneration PT
    14.1 10015919 - Eye disorders 10068530 Macular degeneration progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004857-24 Sponsor Protocol Number: A4321001 Start Date*: 2005-03-07
    Sponsor Name:Pfizer Global Research and Development
    Full Title: A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associate...
    Medical condition: Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    5.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001498-13 Sponsor Protocol Number: 24/2006/O/Sper Start Date*: 2006-09-19
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Effetti della iniezione endovitreale di Avastin per il trattamento delle maculopatie essudative
    Medical condition: exudative maculopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025425 Maculopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018637-21 Sponsor Protocol Number: 1 Start Date*: 2013-11-20
    Sponsor Name:Universitätsklinikum Schleswig-Holstein UKSH
    Full Title: Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrha...
    Medical condition: exsudative age-related macular degeneration with acut submacular hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10055305 Macula lutea hemorrhage LLT
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003763-22 Sponsor Protocol Number: BAY73-4506/15984 Start Date*: 2014-07-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degen...
    Medical condition: neovascular age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    18.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000243-24 Sponsor Protocol Number: MD7114987 Start Date*: 2011-06-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: An open-label, phase 2a study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular agerelated macular degeneration
    Medical condition: Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003899-31 Sponsor Protocol Number: DBC-AMD-001-D Start Date*: 2018-05-28
    Sponsor Name:DOBECURE, S.L
    Full Title: International, multicenter, randomised, blind, sham-controlled, 2x2 cross over phase III clinical trial to assess the efficacy and security of an intravitreal injection of Etamsylate in the improv...
    Medical condition: Aged related macula degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:42:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA